Pipeline
Protein drugs, vaccines and cancer treatment drugs
Lipoxen’s supergenerics pipeline contains a range of new product candidates which are currently under development either in-house or with biotechnology and pharmaceutical partners. These new products in Lipoxen’s pipeline have a total market potential of several billion dollars.
The new products are based on Lipoxen’s proprietary drug and vaccine delivery technologies and have been developed to offer improved performance and delivery. Lipoxen’s unique delivery technologies have the potential to create new high-value, differentiated proprietary products from off-patent actives.
Lipoxen also has a range of partnerships with major US, European and Asian biotechnology and pharmaceutical companies to develop new protein therapeutics, vaccines and cancer drugs.